argenex (NASDAQ:ARGX) Price Target Raised to $915.00

argenex (NASDAQ:ARGX) had its price target raised by HC Wainwright from $774.00 to $915.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for argenex’s FY2028 earnings at $47.85 EPS and FY2029 earnings at $55.93 EPS.

ARGX has been the topic of a number of other reports. Piper Sandler boosted their target price on shares of argenex from $750.00 to $820.00 and gave the stock an “overweight” rating in a report on Tuesday, August 26th. Royal Bank Of Canada assumed coverage on shares of argenex in a research note on Monday, August 25th. They issued an “outperform” rating and a $850.00 target price for the company. Stifel Nicolaus set a $882.00 target price on shares of argenex in a research note on Thursday, September 18th. Guggenheim reiterated a “buy” rating and issued a $1,070.00 target price on shares of argenex in a research note on Thursday, September 18th. Finally, Wedbush raised their target price on shares of argenex from $800.00 to $880.00 and gave the company an “outperform” rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $851.70.

argenex Stock Performance

Shares of ARGX opened at $818.50 on Friday. The firm has a market cap of $50.40 billion, a P/E ratio of 35.14, a PEG ratio of 0.94 and a beta of 0.45. argenex has a twelve month low of $510.05 and a twelve month high of $855.46. The firm’s 50 day moving average price is $769.14 and its two-hundred day moving average price is $654.84.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. On average, sell-side analysts anticipate that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenex

Hedge funds and other institutional investors have recently modified their holdings of the stock. WPG Advisers LLC bought a new stake in shares of argenex during the first quarter worth $37,000. Mather Group LLC. bought a new stake in shares of argenex during the third quarter worth $50,000. Brooklyn Investment Group grew its stake in shares of argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after buying an additional 38 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock worth $63,000 after buying an additional 75 shares during the last quarter. Finally, MAI Capital Management grew its stake in shares of argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after purchasing an additional 78 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.